Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Next Previous
Trial Profile

Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anetumab ravtansine (Primary) ; Pembrolizumab
  • Indications Malignant-mesothelioma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 23 Sep 2023 Planned End Date changed from 8 Jul 2024 to 21 Sep 2024.
    • 12 Sep 2023 Results assessing whether anetumab ravtansine is safe to administer with the PD-1 inhibitor pembrolizumab, and whether this combination was more effective than pembrolizumab alone in patients with pleural mesothelioma presented at the 24th World Conference on Lung Cancer.
    • 21 Jul 2023 Planned End Date changed from 16 Mar 2023 to 8 Jul 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top